MedTrace Logo

14.0- 3.0- 3.0- η Protein With Rheumatoid Arthritis

NCT05366608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 188

Last updated 2022-05-09

No results posted yet for this study

Summary

Aim of work: to explore the potential association between serum 14.0-3.0-3.0- η protein level with disease activity and bone mineral density (BMD) in Egyptian patients with rheumatoid arthritis (RA).

188 patients with RA and 192 matched controls were enrolled. The RA activity parameters were evaluated in RA patients. BMD was measured. Serum level of 14.0- 3.0- 3.0- η protein and IL\_.6 were estimated for all participants by ELISA.

Conditions

  • Disease Activity

Interventions

DIAGNOSTIC_TEST

Serum level of 14.0- 3.0- 3.0- η protein and IL_.6

Serum level of 14.0- 3.0- 3.0- η protein and IL\_.6 were estimated for all participants by ELISA.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Yasmin A Abdelsalam, MD · Mansoura University Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-03-01
Completion
2022-03-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366608 on ClinicalTrials.gov